Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible male and female subjects, aged 18 years or older~* Must have at least moderately active SLE, as defined as SLE Disease Activity Index-2000 (SLEDAI-2K) score greater than or equal to \[\>=\] 6 at screening visit~* At least 4 of the 11 American college of rheumatology (ACR) classification criteria for SLE (diagnosed \>= 6 months prior to the screening visit)~* Be seropositive for anti-nuclear antibodies (ANA) and/or anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibodies~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Subjects have demyelinating disorder~* Severe central nervous system SLE~* Use of cyclophosphamide within 3 months of the screening visit~* Urine protein:creatinine ratio (UPCr) \>= 2 milligram per milligram (mg/mg) per day~* Other protocol defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atacicept 75 mg (Type: EXPERIMENTAL): None
- Atacicept 150 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).